<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:10pt Times New Roman, serif; }
 .font4 { font:17pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font4">J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font2" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font2" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font2" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font2" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font3">Phase 1-2 for ALK-positive NSCLC, while HLX07, bevacizumab, and cetuximab are cleared to commence human trials.</span></p>
<p><span class="font1" style="font-weight:bold;">Table 7:1H16 R&amp;D Progress: Biopharmaceuticals and Innovative Chemical Drugs</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Clinical trials approved</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Therapeutic area</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Product name</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Category</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Indications</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Oncology</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Recombinant Humanized Ani-Her2</span></p>
<p><span class="font2" style="font-weight:bold;">Monoclonal Antibody Injection</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Bio 2</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Gastric</span></p>
<p><span class="font2" style="font-weight:bold;">Cancer</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Oncology</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">HLX07(anti-EGFR humanized monoclonal antibody) Injection</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Bio 1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Colorectal</span></p>
<p><span class="font2" style="font-weight:bold;">cancer</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Oncology</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Recombinant Anti-VEGF Humanized</span></p>
<p><span class="font2" style="font-weight:bold;">Monoclonal Antibody Injection</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Bio 2</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">NSCLC</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Metabolism and Alimentary Tract</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Recombinant Human Insulin Injection</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Bio 15</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Diabetes</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Oncology</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">FCN-411(API and Capsules)</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Chern 1.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Anti-tumor</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Clinical trial applied</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Therapeutic area</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Product name</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Category</span></p></td><td style="vertical-align:top;">
<p><span class="font0" style="font-weight:bold;">Indications</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Anti-infecti V e</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">PA 824 tabltes</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Chern 1.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Anti-tubercluosis</span></p></td></tr>
</table>
<p><span class="font0">Source: Company dale, JP Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">Table 8:1H16 R&amp;D progress: Generic drugs with high barriers to entry</span></p>
<p><span class="font0" style="font-weight:bold;">Clinical trials approved</span></p>
<p><span class="font0" style="font-weight:bold;">Therapeutic area &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product name &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Category Indications</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Metabolism and Alimentary Tract</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Dutasteride API &amp;&nbsp;Duodart Sustained</span></p>
<p><span class="font2" style="font-weight:bold;">Release Capsule</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Chern 3+3.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Benign Prostate Hy pertrophy</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Metabolism and Alimentary Tract</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Canagliflozin API &amp;&nbsp;Tablets</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Chern 3.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Diabetes</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Metabolism and Alimentary Tract</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Tofacitinib Citrate API &amp;&nbsp;Tablets</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Chern 3.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Rheumatoid</span></p>
<p><span class="font2" style="font-weight:bold;">Arthritis</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Oncology</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Enzalutamide API &amp;&nbsp;Soft Capsule</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Chern 3.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Anti-tumor</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Metabolism and Alimentary Tract</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Apremilast API &amp;&nbsp;Tablets</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Chern 3.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Psoriasis</span></p>
<p><span class="font2" style="font-weight:bold;">Arthritis</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Central Nervous Sy stem</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Quetiapine Fumarate Extended-Release Capsule</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Chern 5</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Schizophrenia</span></p></td></tr>
</table>
<p><span class="font0">Source: Company data, J.P. Morgan</span></p>
<p><span class="font3" style="font-weight:bold;">Proven track record of M&amp;A capability</span></p>
<p><span class="font3">We think one of Fosun’s competitive advantages is acquiring valuable assets at reasonable prices and integrate its platform (see table below). It continues to invest and explore new business models. For example, in 2015 it acquired 9.73% equity interest in Guahao.com accumulatively and set up strategic cooperation with the company. It also invested RMB36 million in Mingyizhudao as a lead investor for its A-round financing for 15% of its equity interest in October 2015. It plans to cooperate with China life and Taikang group, major insurance companies in China, to build an “integrated insurance+ sendee +pharmaceuticals” platform.</span></p>
<p><span class="font3">Recently Fosun announced the acquisition of 86% stake in Gland Pharma Ltd., an Indian developer and manufacturer of generic injectables, for USD 1,26bn. The acquisition is one of the biggest among any Indian company bought by a Chinese</span></p>
<p><span class="font2" style="font-weight:bold;">13</span></p>
</body>
</html>